Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

scancell biontech cancer t cell 1

News and Trends 9 Jan 2018

Scancell and BioNTech Will Combine Their Expertise to Fight Cancer

Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […]

January 9, 2018 - 3 minutesmins - By Alex Dale

ablynx acquisition novo nordisk

More News! 9 Jan 2018

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […]

January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

T cell therapy adaptimmune 1

News and Trends 9 Jan 2018

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […]

January 9, 2018 - 3 minutesmins - By Alex Dale

warts treatment HPV cytovation2 1

News and Trends 8 Jan 2018

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells

Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […]

January 8, 2018 - 3 minutesmins - By Alex Dale

galapagos proqr fibrosis rna

News and Trends 8 Jan 2018

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

minoryx rare disease trial 1

News and Trends 8 Jan 2018

And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial

Minoryx Therapeutics has dosed the first patient in its Phase II/III trial for patients with adrenomyeloneuropathy, a condition that affects 1 in 17,000 newborns worldwide. Minoryx Therapeutics focuses on the development of new drugs for orphan diseases like adrenomyeloneuropathy. The first two patients in ADVANCE, a Phase II/III clinical trial of MIN-102, have started their treatment. The trial, […]

January 8, 2018 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

topivert ulcerative colitis trial

News and Trends 8 Jan 2018

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

liquid biopsy prostate cancer angle 1

News and Trends 8 Jan 2018

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […]

January 8, 2018 - 3 minutesmins - By Alex Dale

antibiotic resistance skin patch 1

News and Trends 8 Jan 2018

This Skin Patch Could Slow the Rate of Antibiotic Resistance

Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […]

January 8, 2018 - 3 minutesmins - By Alex Dale

alzheimers disease acimmune andrea pfeifer 1

Interview 8 Jan 2018

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […]

January 8, 2018 - 8 minutesmins - By Evelyn Warner

Mellissa Fisher microbial me

More News! 6 Jan 2018

A Self-Portrait of the Microbes that Live on our Skin

Is a portrait fully complete without portraying the millions of bacteria that live on our skin? Mellissa Fisher makes them the focus of her self-portraits. British artist Mellissa Fisher creates quite unique portraits. The material for her face sculptures is agar rich in nutrients, the same one that scientists use to grow bacteria and fungi […]

January 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

takeda tigenix acquisition stem cell therapy

News and Trends 5 Jan 2018

Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech

Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […]

January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT